# Study on MK-3475 Plus Chemotherapy Versus Chemotherapy Alone in Recurrent, Platinum-resistant Ovarian Cancer

> **NCT03539328** · PHASE2 · UNKNOWN · sponsor: **Fondazione IRCCS Istituto Nazionale dei Tumori, Milano** · enrollment: 138 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Gemcitabine
- **DRUG:** Paclitaxel
- **DRUG:** Liposomal Doxorubicin

## Key facts

- **NCT ID:** NCT03539328
- **Lead sponsor:** Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-06
- **Primary completion:** 2022-04
- **Final completion:** 2022-04
- **Target enrollment:** 138 (ESTIMATED)
- **Last updated:** 2018-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03539328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03539328, "Study on MK-3475 Plus Chemotherapy Versus Chemotherapy Alone in Recurrent, Platinum-resistant Ovarian Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03539328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*